Mushrooms Recalled Nationwide Over Listeria Fears
Harvest NYC Inc. has announced a nationwide recall of its 200g packages of Enoki Mushrooms due to potential Listeria monocytogenes contamination.
Newsweek has reached out to Harvest NYC Inc. on Sunday for comment.
Listeria contamination poses serious health risks, particularly for vulnerable populations including young children, elderly individuals, pregnant women, and those with compromised immune systems.
Infections can lead to severe symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain, and diarrhea. For pregnant women, listeriosis can result in miscarriages and stillbirths. Even healthy individuals may experience short-term symptoms from exposure to the bacteria.
The company, which is based in Brooklyn, issued its announcement on April 16, which was published by the U.S. Food & Drug Administration (FDA) on its website April 18. The recall was triggered after samples collected from a store in Buffalo, New York, tested positive for the bacteria during analysis by the New York State Department of Agriculture and Markets Food Laboratory.
The recalled products are packaged in 200g green plastic containers marked with UPC barcode 6975730520101 on the back label. They are distributed by Hofood99 Inc. of Oakland Gardens, New York, and sold in retail stores across the country. The affected mushrooms were purchased between January 11-31, 2025.
Consumers who have these products are urged to either destroy them immediately or return them to their place of purchase for a full refund.
No illnesses have been reported to date in connection with the contaminated products.
U.S. Food & Drug Administration (FDA) in a statement on its website: "When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company."
Harvest NYC Inc. in a statement: "Consumers who have purchased 200g packages of Enoki Mushroom from January 11-31, 2025, are urged to destroy the products immediately or return them to the place of purchase for a full refund. Consumers with questions may contact the company at (718) 596-0777."
Consumers should check any enoki mushrooms in their refrigerators against the recall information to ensure they don't consume potentially contaminated products.
Related Articles
Cookies Recalled Over 'Rancid Taste' Issued Risk WarningFDA Withheld Details of Deadly E. coli Outbreak in 15 States-What We KnowTortilla Chip Recall as FDA Issues Risk WarningCandy Recall in 8 States As FDA Sets Risk Level
2025 NEWSWEEK DIGITAL LLC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
AG pushes back on federal abortion medication restrictions
BOSTON (SHNS) – Attorney General Andrea Campbell implored federal regulators Thursday to eliminate medication abortion restrictions on prescribers and pharmacies, arguing Massachusetts already has 'robust' guardrails in place to protect patient safety. Campbell, along with AGs from California, New York and New Jersey, want the U.S. Food and Drug Administration to eliminate its Risk Evaluation and Mitigation Strategy (REMS) program for mifepristone — or at least stop applying certain parts of it to the four petitioning states. The program outlines certification requirements for health care providers and pharmacies to dispense mifepristone, plus paperwork that patients must sign. About 65% of abortions in Massachusetts in 2023 were medication abortions, according to the 64-page citizen petition Campbell co-filed Thursday. The FDA says REMS programs are used for drugs with 'serious safety concerns to help ensure the benefits of the medication outweigh its risks.' Campbell's office contends the mifepristone requirements impose 'burdensome restrictions on access to medication abortion while not meaningfully improving patient safety, and that these restrictions severely impede patient access by reducing the number of prescribers and pharmacies authorized to dispense this FDA-approved medication.' 'The Mifepristone REMS Program also imposes an undue burden on pregnant patients experiencing miscarriage and early pregnancy loss who seek treatment at emergency departments,' the petition says. 'For instance, the administrative requirements imposed by the REMS can effectively discourage emergency departments from carrying mifepristone in their pharmacies.' Reduced access to mifepristone can particularly impact patients in rural and medically underserved areas, the petition added. The Democratic AGs teamed up in response to U.S. Health and Human Services Secretary Robert Kennedy recently instructing FDA Commissioner Martin Makary to pursue a 'complete review' of mifepristone and labeling requirements. The FDA is required to respond to their petition within 180 days by either approving, denying or dismissing it — or providing a 'tentative response' about why the agency is unable to reach a decision yet, according to federal regulations. In response to the Trump administration, Beacon Hill lawmakers are escalating their focus on shoring up protections for reproductive and transgender care. A Sen. Cindy Friedman bill (S 2522) that's gaining traction would tighten the 2022 abortion shield law, including by requiring hospitals to provide emergency abortion care and allowing provider practices, rather than specific prescriber names, to appear on medication abortion labels. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
4 hours ago
- Yahoo
Patient records go digital to 'co-ordinate care'
All patient records at a hospital are to go digital as part of a major step "in modernising patient care". The new Electronic Patient Record (EPR) will be switched on at Northampton General Hospital (NGH) from Saturday 28 June. It has been developed by the software system Nervecentre, and is designed to bring all patient notes and information into "one single, secure digital format". William Monaghan, from NGH, described it as a "pivotal moment" and said he hoped it would mean "safer and more co-ordinated care". A hospital spokesperson said the electronic system would "enable clinical teams to access real-time information about a patient's care, helping them make quicker, safer and better-informed decisions". Patient records are currently stored in a combination of paper files and digital systems, but will be replaced by "a central, streamlined platform that enhances efficiency and reduces duplication". Mr Monaghan, group chief digital information officer, said: "This is a pivotal moment for NGH and our patients. "The new EPR system puts essential information at our clinical teams' fingertips, helping them deliver safer, more co-ordinated care. "While there may be a few teething problems as we go live, this investment in digital infrastructure will transform how we work, giving our teams more time to focus on what matters most: caring for patients." The hospital said staff would be using secure, hospital-owned mobile devices, like tablets and iPhones, at patients' bedsides. It means staff will be able to view the latest medical information instantly, spend less time on administration, avoid asking patients to repeat their history many times - and improve co-ordination between departments and services. All patient information will be kept secure, it confirmed. Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X. Hospital's A&E told to make urgent improvements Hospital staff invited to resign to reduce workforce Hospital ward is 'safe' despite concern over falls Northampton General Hospital
Miami Herald
5 hours ago
- Miami Herald
Baby swabs and nasal swabs recalled for possible fungus in swab parts
Swabs for teething babies and adult noses have been recalled because they might have a microbial contamination 'identified as fungi in cotton swab components.' That's what manufacturer Church & Dwight said in its notice announcing the recall of Orajel Baby Teething Swabs, Zicam Cold Remedy Nasal Swabs and Zicam Nasal AllClear Swabs from stores across the United States, including Puerto Rico. The lots and expiration dates involved? All. READ MORE: Recalled UTI drug could have deadly microbial contamination What can contaminated swabs do? Swabs with a microbial contamination can cause 'serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injurie,' the recall notice states. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' Exactly which Orajel and Zicam swabs are recalled? ▪ Zicam Cold Remedy Nasal Swabs carry UPC No. 732216301205. ▪ Zicam Nasal AllClear Swabs, which were discontinued in December, carry UPC No. 732216301656. ▪ Orajel baby swabs carry UPC No. 310310400002. What should you do now? If you have the swabs, throw them in the trash or, for a refund, reach out go Church & Dwight either online or by calling 800-981-4710. Questions can be directed to that phone number, 9 a.m. to 5 p.m., Monday through Friday. If you think you or your baby is having a medical issue caused by these swabs, go see a medical professional. Then, notify the FDA's MedWatch Adverse Event Program, either by filling out a form online or by requesting a reporting form at 800-332-1088. Then, third, call Church & Dwight.
